Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Promising Medication for Chronic Obstructive Pulmonary Disease?

Vasileiadis, Ioannis; Goudis, Christos A.; Giannakopoulou, P; Liu, Tong

doi:10.1080/15412555.2018.1432034

Cited by 23 publications

(15 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COPD consists of not only a persistent lung inflammation that leads to reduced airflow but also systemic inflammation that leads to comorbidities including cardiovascular disease. Studies have implicated the renin angiotensin system (RAS) in the development of pulmonary and extrapulmonary disorders in COPD thus highlighting the potential therapeutic benefit of RAS blockade in subjects with COPD 32 . Therefore, we examined whether the angiotensin-II AT1 receptor antagonist losartan would significantly reduce lung inflammation in mice chronically exposed to CS and thus be a promising medication for the treatment of COPD and comorbid cardiovascular disease.…”

Section: Discussionmentioning

confidence: 99%

Losartan does not inhibit cigarette smoke-induced lung inflammation in mice

Hepworth

Passey

Seow

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease largely caused by cigarette smoking (CS) and is characterized by lung inflammation and airflow limitation that is not fully reversible. Approximately 50% of people with COPD die of a cardiovascular comorbidity and current pharmacological strategies provide little benefit. Therefore, drugs that target the lung and the cardiovascular system concurrently may be an advantageous therapeutic strategy. The aim of this study was to see whether losartan, an angiotensin-II AT1a receptor antagonist widely used to treat hypertension associated with cardiovascular disease, protects against CS-induced lung inflammation in mice. Male BALB/c mice were exposed to CS for 8 weeks and treated with either losartan (30 mg/kg) or vehicle daily. Mice were euthanized and bronchoalveolar lavage fluid (BALF) inflammation, and whole lung cytokine, chemokine and protease mRNA expression assessed. CS caused significant increases in BALF total cells, macrophages, neutrophils and whole lung IL-6, TNF-α, CXCL-1, IL-17A and MMP12 mRNA expression compared to sham-exposed mice. However, losartan only reduced CS-induced increases in IL-6 mRNA expression. Angiotensin-II receptor expression was reduced in lung tissue from CS-exposed mice. In conclusion, losartan did not inhibit CS-induced BALF cellularity despite reducing whole lung IL-6 mRNA and Ang-II receptor expression.

show abstract

Section: Discussionmentioning

confidence: 99%

Losartan does not inhibit cigarette smoke-induced lung inflammation in mice

Hepworth

Passey

Seow

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…It has also been reported that ARBs ameliorate pneumonia in COVID-19 patients [ [176] , [177] , [178] , [179] ], after viral infections [ 6 , [180] , [181] , [182] , [183] , [184] , [185] , [186] ], in diabetic patients [ 187 ] and in chronic obstructive pulmonary disease [ [188] , [189] , [190] ]. Improved clinical outcome after ARB treatment of COVID-19 patients is associated with reduced IL-6 in peripheral blood, increased CD3 and CD8 T cell counts and reduced peak viral load [178 ] and lower concentrations of high-sensitivity C-reactive protein (hs-CRP) and procalcitonin (PCT) [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Candesartan could ameliorate the COVID-19 cytokine storm

Elkahloun¹,

Saavedra²

2020

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this is the first study to examine the association between β-blocker use and risk of COPD compared specifically with other antihypertensive drugs. This is important because other cardiovascular drugs (ACE inhibitors and angiotensin II receptor antagonists) also seem to have beneficial effects in COPD [27], [28].…”

Section: Discussionmentioning

confidence: 99%

β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease – A Danish Nationwide Study of 1·3 Million Individuals

et al. 2019

View full text Add to dashboard Cite

Background The possible association between β-adrenoceptor antagonists (β-blockers) and risk of COPD is controversial. The objective of the present study was to test whether β-blocker use is associated with susceptibility to the disease. Methods A total of 301,542 new users of β-blockers and 1,000,633 new users of any other antihypertensive drugs aged 30–90 years without any history of COPD hospitalizations were included in the present study and followed in the Danish National Patient Registry for incident admissions for COPD and COPD death between 1995 and 2015. Multiple adjusted cox regression models were used to examine the association between use of β-blockers and COPD hospitalization. Additionally, subgroup analyses based on underlying diseases at baseline or duration of treatment were performed. Findings People treated with β-blockers continuously for more than 6 months had a lower risk of COPD hospitalization during follow-up compared to people treated with any other antihypertensive drugs (adjusted hazard ratio [HR adjusted ] 0·80, 95% CI 0·79–0·82). Risk of COPD hospitalization was lowered in the groups treated with β-blockers among patients with ischemic heart disease (0·72, 0·69–0·75), cardiac arrhythmias (0·76, 0·72–0·80), asthma (0·69, 0·61–0·79), hypertension (0·91, 0·86–0·96), and diseases of the pulmonary circulation (pulmonary embolism and cor pulmonale) (0·72, 0·59–0·87). All-cause mortality as well as risk of COPD death during follow-up was lower in the group treated with β-blockers compared to the group treated with any other antihypertensive drugs (0·56, 0·53–0·59). Interpretation Treatment with β-blockers seems to reduce risk of COPD hospitalization and mortality compared to treatment with any other antihypertensive drugs. Funding The Danish Council for Independent Research in Denmark (grant no. 4183-00569B), The Research Foundation of Health Science in Region Zealand (grant no. RSSF2017000661 and no. 15-000342), The Research Foundation of Medical Science (A.P. Møller Foundation, grant no. 16-68), The Research Foundation in memory of King Christian 10th (grant no. 142/2017), Aase & Ejnar Danielsen's Research Foundation (grant no. 10-001946), and Lundbeck Foundation (grant no. R252-2017-1690).

show abstract

Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Promising Medication for Chronic Obstructive Pulmonary Disease?

Cited by 23 publications

References 97 publications

Losartan does not inhibit cigarette smoke-induced lung inflammation in mice

Losartan does not inhibit cigarette smoke-induced lung inflammation in mice

Candesartan could ameliorate the COVID-19 cytokine storm

β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease – A Danish Nationwide Study of 1·3 Million Individuals

Contact Info

Product

Resources

About